Peru VUCE and SUCE: Electronic Submission for Medical Device Registration

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

Regulatory information verified as of October 29, 2026

1. Key takeaways

Submission of Peruvian medical device sanitary registrations (Registro Sanitario, RS) is integrated into the foreign trade single window system (Ventanilla Única de Comercio Exterior, VUCE), with the Single Foreign Trade Application (Solicitud Única de Comercio Exterior, SUCE) serving as the procedural entry point. The stage where applications are most frequently returned is not the technical review but the formal (admissibility) examination. The specific list of common formal-examination return reasons is a practical estimate; the verifiable procedural framework comes from D.S. N° 011-2026-SA (Nuevo Texto Único de Procedimientos Administrativos (TUPA) del MINSA, published on 2026-07-21 in El Peruano) and D.S. N° 016-2011-SA (published on 2011-07-27). For foreign manufacturers this division of labor has a direct planning consequence: the technical dossier answers the question of whether the product is acceptable, while the formal layer answers the question of whether the application exists at all, and the second question is always asked first.

The GRZAN working principle is to manage formal examination as an independent work stage: it occurs before the technical review, yet it determines whether the review clock actually starts running.

2. Legal basis

RegulationNumberPublication dateProvisions / key points
Nuevo Texto Único de Procedimientos Administrativos (TUPA) del MINSAD.S. N° 011-2026-SA2026-07-21 (El Peruano)Approves the new TUPA, repealing D.S. N° 001-2016-SA and its subsequent amendments; uniformly governs administrative procedures, requirements, deadlines, fees, and forms
Reglamento para el Registro, Control y Vigilancia Sanitaria de Productos Farmacéuticos, Dispositivos Médicos y Productos SanitariosD.S. N° 016-2011-SA2011-07-27 (El Peruano)Art. 124 and 125 (dossiers); Art. 136 (maximum evaluation periods in calendar days)
Ley del Procedimiento Administrativo GeneralLey N° 274442001-04-11General administrative procedure law; procedural basis for negative administrative silence, reconsideration, and appeal
Modificatoria del D.S. N° 016-2011-SAD.S. N° 016-2017-SA2017-06-07Substantially amends Art. 124, 125, 127, 130, among others

Regulatory information verified as of October 29, 2026. The review clocks of 22 / 44 / 66 working days (IVD: 30 working days) originate from the 2026 new TUPA procedure tables and constitute Category C data (industry database, source-verified; individual line items not verified one by one).

3. Expert insights

Insight one: formal examination is an entry gate that assesses whether the application exists, not whether the product is safe. Mechanically, after VUCE receives the SUCE submission, the competent authority first checks the qualification of the entity, the procedure code, the fee payment receipt, and the formal completeness of the document list. This step does not evaluate technical content, so return reasons fall almost entirely on admissibility rather than on whether the dossier is well written. Preparing an exhaustively detailed technical dossier while neglecting forms and codes amounts to spending time on a layer that will never be read.

Insight two: the starting point of the review clock determines the scheduling strategy. Under the 2026 new TUPA procedure tables, Class I is 22 working days, Class II is 44 working days, Class III and Class IV are 66 working days, and in vitro diagnostic devices (Dispositivo Médico de Diagnóstico In Vitro, IVD) are 30 working days (Category C data). These clocks start from formal acceptance of the application; time spent in formal examination is not counted. The real scheduling risk lies in the fact that a return, correction, and resubmission resets the entry gate, and the review clock restarts with it.

Insight three: observation letters and the general administrative procedure law together form the remedies framework. Under the TUPA (Category C data), failure to respond to Observaciones within 30 working days constitutes grounds for denial; against a denial, a reconsideración (Reconsideración) may be filed with the Executive Director of the Medical Devices and Sanitary Products Directorate within 15 working days, with an apelación (Apelación) available at the next level; the procedural basis is Ley N° 27444 (published on 2001-04-11). The remedy logic of this procedure is negative administrative silence (Silencio Administrativo Negativo): expiry of the period without a response does not constitute approval, and shipments must not be scheduled on that basis.

Insight four: the calendar day ceiling of Art. 136 of D.S. N° 016-2011-SA coexists with the TUPA working day clocks. Art. 136 sets maximum evaluation periods of 30 calendar days for Class I, 60 for Class II, and 90 for Classes III/IV (statutory ceiling of the regulation, Category A data). The two measures differ in unit: one is the calendar day ceiling set by the regulation, the other is the working day procedural clock of the TUPA. GRZAN tracks both sets of figures in scheduling and commits externally to the more conservative one.

4. Practical recommendations

  1. Before submission, check the application item by item against the requirements list of the new TUPA, confirming that the procedure code, the fee payment receipt, and the entity qualification number are mutually consistent.
  2. Manage formal examination as an independent milestone, schedule the correction window backwards, and avoid triggering the failure to correct within 30 working days, which constitutes grounds for denial.
  3. Cross-check the TUPA working day clocks against the calendar day ceilings of Art. 136 of D.S. N° 016-2011-SA, and commit externally to the conservative value.
  4. If no response is received by the deadline, proceed under negative administrative silence through Reconsideración / Apelación, and do not schedule shipments on the assumption of approval.
  5. Complete a unified terminology proofread of all Spanish-language documents before submission, so the same product does not appear under different names in the application form and the technical dossier.

5. Verification checklist

□ The procedural entry point has been confirmed as the SUCE submission through VUCE.

□ Requirements, forms, and fee payment receipts have been checked against the new TUPA of D.S. N° 011-2026-SA.

□ The expected clocks of 22 working days (Class I), 44 working days (Class II), 66 working days (Classes III/IV), and 30 working days (IVD) have been recorded (Category C).

□ A deadline reminder has been set for correction of Observaciones within 30 working days.

□ The 15 working day reconsideration period and the competent authority have been confirmed.

□ Common formal-examination return reasons have been confirmed as managed under a practical estimate, not an official statutory list.

□ Regulatory information verified as of October 29, 2026.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives. For inquiries, contact info@grzanglobal.com.

*GRZAN Regulatory Affairs Team*

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail